MX2022006132A - Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco. - Google Patents
Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco.Info
- Publication number
- MX2022006132A MX2022006132A MX2022006132A MX2022006132A MX2022006132A MX 2022006132 A MX2022006132 A MX 2022006132A MX 2022006132 A MX2022006132 A MX 2022006132A MX 2022006132 A MX2022006132 A MX 2022006132A MX 2022006132 A MX2022006132 A MX 2022006132A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- antibody
- drug conjugates
- avb6
- seq
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 3
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan nuevos anticuerpos anti-avß6 y conjugados de anticuerpo-fármaco y métodos para usar tales anticuerpos anti-avß6 y conjugados de anticuerpo-fármaco para tratar el cáncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962943959P | 2019-12-05 | 2019-12-05 | |
US202063012584P | 2020-04-20 | 2020-04-20 | |
PCT/US2020/063390 WO2021113697A1 (en) | 2019-12-05 | 2020-12-04 | Anti-avb6 antibodies and antibody-drug conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022006132A true MX2022006132A (es) | 2022-06-17 |
Family
ID=76222033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022006132A MX2022006132A (es) | 2019-12-05 | 2020-12-04 | Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco. |
Country Status (12)
Country | Link |
---|---|
US (2) | US11827709B2 (es) |
EP (1) | EP4069297A4 (es) |
JP (1) | JP2023504187A (es) |
KR (1) | KR20220110231A (es) |
CN (1) | CN114828887A (es) |
AU (1) | AU2020397070A1 (es) |
BR (1) | BR112022009570A2 (es) |
CA (1) | CA3159414A1 (es) |
IL (1) | IL293195A (es) |
MX (1) | MX2022006132A (es) |
TW (1) | TW202134281A (es) |
WO (1) | WO2021113697A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL293195A (en) | 2019-12-05 | 2022-07-01 | Seagen Inc | Anti-avb6 antibodies and antibody-drug conjugates |
WO2024088283A1 (zh) * | 2022-10-26 | 2024-05-02 | 同润生物医药(上海)有限公司 | 人源化的l1cam抗体药物偶联物 |
WO2024097816A1 (en) | 2022-11-03 | 2024-05-10 | Seagen Inc. | Anti-avb6 antibodies and antibody-drug conjugates and their use in the treatment of cancer |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962643A (en) | 1991-07-11 | 1999-10-05 | The Regents Of The University Of California | Integrin β subunit and uses thereof |
ES2311131T3 (es) | 1997-08-08 | 2009-02-01 | The Regents Of The University Of California | Tratamiento de la fibrosis hepatico con anticuerpos contra la integrina alfa-v-beta6. |
AU2002258808A1 (en) | 2001-04-30 | 2002-11-11 | Eli Lilly And Company | Humanized antibodies |
BRPI0308585B8 (pt) | 2002-03-13 | 2021-05-25 | Biogen Idec Inc | anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna |
US20040048312A1 (en) | 2002-04-12 | 2004-03-11 | Ronghao Li | Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof |
US7241598B2 (en) | 2004-06-29 | 2007-07-10 | The Chinese University Of Hong Kong | Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering |
EP1797182A2 (en) | 2004-10-05 | 2007-06-20 | Wyeth a Corporation of the State of Delaware | Methods and compositions for improving recombinant protein production |
WO2006099141A2 (en) | 2005-03-10 | 2006-09-21 | Morphotek, Inc. | Anti-mesothelin antibodies |
RU2007142523A (ru) | 2005-05-18 | 2009-06-27 | БИОГЕН ИДЕК Инк. (US) | Способы лечения фиброзных состояний |
CN104072614B (zh) | 2005-07-08 | 2017-04-26 | 生物基因Ma公司 | 抗-αvβ6 抗体及其用途 |
CA2620641A1 (en) | 2005-08-31 | 2007-03-08 | Novo Nordisk Health Care Ag | Human fvii monoclonal antibodies binding the gla domain and use thereof |
KR20090027241A (ko) | 2006-07-10 | 2009-03-16 | 바이오겐 아이덱 엠에이 인코포레이티드 | Smad4-결핍 암의 성장을 억제하기 위한 조성물 및 방법 |
CA2658612C (en) | 2006-08-03 | 2015-11-17 | Astrazeneca Ab | Antibodies directed to .alpha.v.beta.6 and uses thereof |
AU2007354317A1 (en) | 2006-10-19 | 2008-12-04 | Biogen Idec Ma Inc. | Treatment and prevention of chronic asthma using antagonists of integrin alphaVbeta6 |
CL2008001071A1 (es) * | 2007-04-17 | 2009-05-22 | Smithkline Beecham Corp | Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades. |
EP4282428A3 (en) | 2008-01-11 | 2024-03-20 | The University of Tokyo | Anti-cldn6 antibody |
JP5467997B2 (ja) | 2008-03-27 | 2014-04-09 | テルモ株式会社 | 生体吸収性材料およびそれを用いた生体内留置物 |
EP2279209A2 (en) | 2008-05-09 | 2011-02-02 | Ablynx NV | Amino acid sequences directed against integrins and uses thereof |
CA2771441C (en) * | 2009-08-19 | 2016-10-11 | Merck Patent Gmbh | Antibodies for the detection of integrin complexes in ffpe material |
WO2011046309A2 (en) | 2009-10-12 | 2011-04-21 | Korea Research Institute Of Bioscience And Biotechnology | A diagnostic marker for hepatocellular carcinoma comprising anti-fasn autoantibodies and a diagnostic composition for hepatocellular carcinoma comprising antigens thereof |
KR101919170B1 (ko) * | 2010-11-19 | 2018-11-15 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 중화 항-ccl20 항체 |
SG11201404354UA (en) * | 2012-02-17 | 2014-10-30 | Seattle Genetics Inc | ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER |
EP2831104B1 (en) | 2012-03-29 | 2021-04-21 | Biogen MA Inc. | Biomarkers for use in integrin therapy applications |
US10035860B2 (en) * | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
US10035859B2 (en) * | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
EA033403B1 (ru) * | 2013-08-13 | 2019-10-31 | Sanofi Sa | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения |
EP3052523B1 (en) * | 2013-10-01 | 2021-03-10 | Medimmune Limited | Methods of treating and diagnosing alpha-v-beta-6 overexpressing cancer |
EP3592771A4 (en) * | 2017-03-10 | 2020-09-09 | Suzhou Kanova Biopharmaceutical Co., Ltd. | MONOCLONAL ANTIBODIES AGAINST BOTH IL-17A AND IL-17F AND USE THEREOF |
EP3630844A4 (en) * | 2017-05-30 | 2021-03-03 | Chong Kun Dang Pharmaceutical Corp. | NEW ANTI-C-MET ANTIBODY AND ITS USE |
JP2020531521A (ja) * | 2017-08-22 | 2020-11-05 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 抗アルファ(v)ベータ(6)抗体を含有する医薬組成物及び投薬計画 |
GB201814562D0 (en) * | 2018-09-07 | 2018-10-24 | Hummingbird Bioscience Pte Ltd | Vista antigen-binding molecules |
IL293195A (en) | 2019-12-05 | 2022-07-01 | Seagen Inc | Anti-avb6 antibodies and antibody-drug conjugates |
-
2020
- 2020-12-04 IL IL293195A patent/IL293195A/en unknown
- 2020-12-04 CA CA3159414A patent/CA3159414A1/en active Pending
- 2020-12-04 CN CN202080083543.8A patent/CN114828887A/zh active Pending
- 2020-12-04 JP JP2022533071A patent/JP2023504187A/ja active Pending
- 2020-12-04 TW TW109142793A patent/TW202134281A/zh unknown
- 2020-12-04 US US17/112,533 patent/US11827709B2/en active Active
- 2020-12-04 AU AU2020397070A patent/AU2020397070A1/en active Pending
- 2020-12-04 KR KR1020227021011A patent/KR20220110231A/ko unknown
- 2020-12-04 MX MX2022006132A patent/MX2022006132A/es unknown
- 2020-12-04 EP EP20897470.9A patent/EP4069297A4/en active Pending
- 2020-12-04 WO PCT/US2020/063390 patent/WO2021113697A1/en unknown
- 2020-12-04 BR BR112022009570A patent/BR112022009570A2/pt unknown
-
2023
- 2023-10-18 US US18/489,216 patent/US20240076383A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN114828887A (zh) | 2022-07-29 |
KR20220110231A (ko) | 2022-08-05 |
BR112022009570A2 (pt) | 2022-08-02 |
TW202134281A (zh) | 2021-09-16 |
EP4069297A1 (en) | 2022-10-12 |
US11827709B2 (en) | 2023-11-28 |
EP4069297A4 (en) | 2024-02-14 |
IL293195A (en) | 2022-07-01 |
AU2020397070A1 (en) | 2022-07-14 |
US20240076383A1 (en) | 2024-03-07 |
US20210198367A1 (en) | 2021-07-01 |
WO2021113697A1 (en) | 2021-06-10 |
JP2023504187A (ja) | 2023-02-01 |
CA3159414A1 (en) | 2021-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022006132A (es) | Anticuerpos anti alfa-v beta-6 (avb6) y conjugados de anticuerpo-farmaco. | |
EA202092410A1 (ru) | Конъюгаты камптотецина с пептидом | |
ZA201804654B (en) | Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates | |
MY198034A (en) | Tumor-targeted agonistic cd28 antigen binding molecules | |
MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
MX2020002666A (es) | Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato. | |
NZ738979A (en) | Pd-1 antibodies | |
MX2021009138A (es) | Anticuerpos anti-cd228 y conjugados de anticuerpo-farmaco. | |
MD4716B1 (ro) | Anticorpi anti-LAG3 şi fragmente de legare a antigenului | |
RU2014120629A (ru) | Антиген-связывающий белок и его применение в качестве продукта для адресной доставки при лечении рака | |
EA202090800A1 (ru) | Новые анти-cd3-эпсилон антитела | |
NZ586053A (en) | Anti-vegf antibody compositions and methods | |
MX2022003930A (es) | Conjugados de péptido de camptotecina. | |
AR080501A1 (es) | Anticuerpos anti factor determinante antigenico de la muerte programada 1 (anti-pd1) | |
MX2021015337A (es) | Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3. | |
NZ594682A (en) | Fully human antibodies specific to cadm1 | |
AR096601A1 (es) | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso | |
MX2022003517A (es) | Anticuerpos anti-pd l1 y conjugados de anticuerpo-farmaco. | |
MX2022005903A (es) | Métodos para tratar el cáncer de mama her2 positivo con tucatinib en combinación con un conjugado fármaco-anticuerpo anti-her2. | |
NZ610091A (en) | Antibodies | |
MY187325A (en) | Anti-5t4 antibodies and antibody-drug conjugates | |
AU2020380603A8 (en) | Anti-mesothelin eribulin antibody-drug conjugates and methods of use | |
MX2022004875A (es) | Inmunoconjugados de tienoazepina, inmunoconjugados y usos de estos. | |
PE20220392A1 (es) | Moleculas de union a claudina-6 y usos de las mismas | |
MX2018009913A (es) | Aglutinantes max como moduladores myc y sus usos. |